These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 28960265)

  • 1. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
    Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
    Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
    Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
    Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ
    Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
    Yang X; Sexauer A; Levis M
    Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
    Smith CC; Levis MJ; Frankfurt O; Pagel JM; Roboz GJ; Stone RM; Wang ES; Severson PL; West BL; Le MH; Kayser S; Lam B; Hsu HH; Zhang C; Bollag G; Perl AE
    Blood Adv; 2020 Apr; 4(8):1711-1721. PubMed ID: 32330242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.